Meeting
2012 ASCO Annual Meeting
Cost-effectiveness of zoledronic acid (ZOL) in postmenopausal women with early breast cancer receiving adjuvant letrozole.
Authors
Mei Xue
Pharmerit North America, LLC, Bethesda, MD
Mei Xue , Peter Fishman , Marc Botteman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
ER+
Citation
J Clin Oncol 30, 2012 (suppl; abstr 553)
DOI
10.1200/jco.2012.30.15_suppl.553
Abstract #
553
Poster Bd #
3D
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Breakthrough
Delayed versus immediate use of zoledronic acid for postmenopausal patients with ER/PR positive early breast cancer who are using adjuvant letrozole.
First Author: Mai Abdel Gelil
Poster
2011 ASCO Annual Meeting
Zoledronic acid inhibits adjuvant letrozole-associated bone loss in postmenopausal Japanese women with early breast cancer.
First Author: S. Takahashi
Poster
2011 ASCO Annual Meeting
Bone effects of adjuvant tamoxifen (T), letrozole (L), or L plus zoledronic acid (Z) in early breast cancer (EBC): The phase III HOBOE study.
First Author: F. Perrone
Poster
2014 ASCO Annual Meeting
Cost-effectiveness of alternative adjuvant bisphosphonate regimens in postmenopausal women with early breast cancer.
First Author: Katherine Elizabeth Reeder-Hayes